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TB drug resistance in a low endemic area 2004 to 2006:
semi-quantitative drug susceptibility testing and genotyping
Abstract
We determined quantitative levels and genetic mechanisms of resistance in drug resistant clinical
isolates of Mycobacterium tuberculosis sampled over a period of three years (n = 45, 17 of which
MDR). Our results lead us to hypothesize that some strains categorized by standard laboratory
procedures of in vitro drug susceptibility testing as resistant to isoniazid, ethambutol or streptomycin
may still respond to a treatment regimen including these agents.
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We determined the quantitative levels and the genetic mechanisms of resistance in drug-resistant clinical
isolates of Mycobacterium tuberculosis sampled over a period of 3 years (n 45; 17 of the isolate were multidrug
resistant). Our results led us to hypothesize that some strains categorized as resistant to isoniazid, ethambutol,
or streptomycin by standard laboratory procedures of in vitro drug susceptibility testing may still respond to
a treatment regimen that includes these agents.
The treatment of multidrug-resistant (MDR) and exten-
sively drug resistant (XDR) tuberculosis (TB) requires the use
of second-line drugs. These drugs are less effective, more ex-
pensive, and more toxic than the first-line drugs. The rate of
treatment success for drug-resistant TB, particularly MDR-TB
or XDR-TB, is significantly lower than that for drug-suscepti-
ble TB (4, 11). In the laboratory, drug susceptibility testing of
mycobacteria is substantially different from standard proce-
dures in diagnostic bacteriology (3). Thus, rather than deter-
mination of the MICs, a single drug concentration, termed the
critical concentration, is mostly used to categorize a clinical
isolate as susceptible or resistant. These concentrations were
introduced in the past to differentiate wild-type strains from
strains with alterations in drug susceptibility, but they do not
correspond to the drug concentrations present in serum or
infected tissues (12, 17). With growing knowledge about the
mechanisms that underlie drug resistance, it has become clear
that drug resistance is multifaceted and that different muta-
tions may lead to different levels of resistance. However, dif-
ferent levels of phenotypic resistance are not taken into ac-
count by using critical concentrations for in vitro drug
susceptibility testing. This may be the reason why for more
than one-third of cases of MDR-TB, standard short-course
therapy has been found to be an effective treatment (1, 6).
In the study described here, we systematically evaluated
quantitative resistance levels in drug-resistant clinical isolates
of Mycobacterium tuberculosis sampled from 2004 to 2006; the
TB case rates in Switzerland were 8.2/100,000 population in
2004, 7.6/100,000 in 2005, and 6.9/100,000 in 2006. The Bactec
MGIT 960 system (Becton Dickinson Diagnostic Systems,
Sparks, MD) was used for primary isolation and testing for
susceptibility to first-line drugs, according to the manufactur-
er’s instructions; the drug concentrations were 0.1 g/ml for
isoniazid, 1.0 g/ml for rifampin (rifampicin), 5.0 g/ml for
ethambutol, and 100 g/ml for pyrazinamide. From 2004 to
2006, a total of 45 clinical isolates of M. tuberculosis were
categorized in the laboratory as resistant to one or more first-
line drugs on the basis of standard critical concentration test-
ing. The collection of strains investigated included all MDR
strains sampled in Switzerland during that period, thus repre-
senting a nationwide survey for MDR-TB in a country with a
low level of endemicity; MDR strains were submitted to the
Nationales Zentrum fu¨r Mykobakterien as part of its function
as a national reference center. By IS6110 profiling, the MDR
strains were determined to represent independent, nonclonally
related isolates. The panel of clinical isolates was retested for
drug susceptibility at critical concentrations as well as at higher
drug concentrations with the Bactec 460 TB system, as sug-
gested by the manufacturer. The following drug concentrations
were tested: isoniazid at 0.1 g/ml, 0.4 g/ml, 1.0 g/ml, 3.0
g/ml, and 10.0 g/ml; rifampin at 1.0 g/ml, 10.0 g/ml, and
50.0 g/ml; ethambutol at 2.5 g/ml, 5.0 g/ml, 12.5 g/ml, and
50.0 g/ml; streptomycin at 1.0 g/ml, 10.0 g/ml, and 50.0
g/ml; ethionamide at 1.25 g/ml and 12.5 g/ml; amikacin at
1.0 g/ml, 10.0 g/ml, 50.0 g/ml; and ofloxacin 2.0 g/ml and
20.0 g/ml. Interpretation was performed by using the stan-
dard interpretation procedure recommended by BD (resistant
when the growth index for the drug-containing vial was greater
than that for the drug-free control and susceptible when the
growth index for the drug-containing vial was less than that for
the drug-free control).
For molecular profiling, the GenoType MTBDRplus assay
(Hain Lifescience, Nehren, Germany) was used (8, 16). The
GenoType MTBDRplus assay is a reverse hybridization line
probe assay designed for the rapid detection of isoniazid and
rifampin resistance-conferring mutations. For the detection of
mutational alterations associated with resistance to ethambu-
tol or streptomycin, i.e., embB position 306 (10) and rpsL
positions 42 and 87 (7), respectively, PCR-driven gene ampli-
fication and nucleic acid sequence determination were used.
Of 44 isolates found to be resistant to isoniazid at 0.1 g/ml,
13 were found to be susceptible at 0.4 g/ml (Table 1). Ac-
cording to the GenoType MTBDRplus assay, none of these 13
strains with low-level isoniazid resistance had a mutation in
katG, but 11 of the 13 strains with low-level isoniazid resistance
showed an inhA promoter mutation (15C/T), leading to con-
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Mikrobiologie, Universita¨t Zu¨rich, Gloriastrasse 30/32, Zu¨rich CH-
8006, Switzerland. Phone: 41 44 634 26 60. Fax: 41 44 634 49 06.
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comitant resistance to ethionamide (see Table 1 for details and
Table 2 for a summary of the results). It has previously been
shown that the overexpression of InhA leads to low or mod-
erate levels of resistance to isoniazid and ethionamide (13).
Thirty-one isolates were resistant to isoniazid at levels of 1
g/ml or greater. The GenoType MTBDRplus assay detected
the katG S315T mutation in 21 of these isolates. This particular
mutation is the most frequent isoniazid resistance-conferring
mutation in clinical strains (20). In our analysis, the isolates
harboring the katG S315T mutation displayed resistance to
various levels of isoniazid, ranging from 1 g/ml to more than
10 g/ml. One isolate showed a katG mutation, which led to
the loss of hybridization of the katG wild-type probe but no
binding to a specific mutated probe. Two isolates showed a
katG and an inhA promoter mutation in parallel; in four iso-
lates, a 15C/T inhA promoter mutation was found. All iso-
lates harboring inhA promoter mutations were also resistant to
ethionamide.
Nineteen isolates were found to be resistant to rifampin. All
rifampin-resistant isolates exhibited a phenotype of high-level
drug resistance (50 g/ml) and harbored well-known resis-
tance mutations. The most frequent rpoB mutation in our
collection of rifampin-resistant isolates was S531L (15 of 19
isolates), 2 isolates showed an H526Y mutation, and 1 isolate
each had a H526D and a D516V mutation (Table 1). One
isolate showed a rifampin-monoresistant phenotype and was
susceptible to isoniazid, ethambutol, streptomycin, and pyrazin-
amide. Seventeen isolates showed simultaneous intermediate
or high-level resistance to isoniazid and thus represented bona
fide MDR strains. No XDR phenotype was present in our
collection of MDR isolates, as the isolates remained suscepti-
ble to either the fluoroquinolones or the injectable second-line
antibiotics (Table 1).
Given the small difference between the drug concentration
used for in vitro drug susceptibility testing and the natural drug
susceptibility of wild-type isolates of M. tuberculosis, testing for
susceptibility to ethambutol is particularly problematic (14).
Ethambutol resistance was mainly found in MDR strains. Fif-
teen isolates had MICs above 2.5 g/ml, with 11/15 isolates
displaying resistance to 5 g/ml or greater. Two isolates
showed a MIC of 12.5 g/ml, but interestingly, no high-level
resistance to ethambutol at 50 g/ml was observed. In eight
isolates, the previously described mutation at position 306 in
embB was found by nucleic acid sequencing (10); these isolates
displayed resistance to ethambutol at a concentration of at
least 2.5 g/ml.
Streptomycin, amikacin, and ofloxacin were tested only with
selected clinical isolates, in particular, MDR strains. Two iso-
lates showed ofloxacin resistance at 2.0 g/ml but susceptibility
at 20.0 g/ml; both isolates were susceptible to amikacin (Ta-
ble 1) and capreomycin (data not shown). One isolate was
found to have high-level resistance to amikacin, with a MIC
above 50.0 g/ml; sequence analysis revealed the specific ami-
noglycoside resistance-conferring mutation A1408G in 16S
rRNA (18). For streptomycin, there was a strict correlation
between the genetic mechanism of resistance and the pheno-
typic resistance level conferred. While mutations in rpsL in
general mediate high-level drug resistance, a significant part of
clinical strains categorized as drug resistant exhibit a low-level-
resistance phenotype and have no mutational target alteration
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in rpsL (15). Of 16 isolates tested, 13 showed resistance to
streptomycin at 1.0 g/ml. Five isolates showed a low- to in-
termediate-level-resistance phenotype and susceptibility to the
drug at 10.0 g/ml. All seven isolates displaying a high-level-
resistance phenotype (resistant to 50.0 g/ml) harbored the
no-cost Lys3Arg alteration at position 42 of rpsL (3), indicat-
ing significant clinical selection pressure for this particular
mutation (2, 19).
Quantitative drug susceptibility testing is essential for the
recognition of residual drug activity against infecting M. tuber-
culosis strains. According to our data, no high-level ethambutol
resistance exists. It thus remains to be determined whether an
in vitro resistant phenotype implies the ineffectiveness of
ethambutol in vivo, in particular as a component of combina-
tion therapy. In contrast, isolates displaying rifampin resistance
were always high-level resistant, with MICs of 50 g/ml.
While promoter alterations in inhA result in low-level isoniazid
resistance, they are associated with significant resistance to
ethionamide. Some evidence indicates that isoniazid may be a
valuable antibiotic, despite the presence of a low- or interme-
diate-level-resistance phenotype (5, 9). The distribution of iso-
niazid resistance-associated mutations in isoniazid-monoresis-
tant isolates was different from that in multidrug-resistant
isolates, with mutations in the inhA promoter region and, thus,
low-level resistance being more common in monoresistant
strains.
Taken together, our data indicate that some first-line drugs
may be considered therapeutic treatment options, despite the
presence of in vitro resistance at the critical concentration.
Diagnostic mycobacteriology would benefit from standardized
measures of quantitative drug susceptibility testing, in partic-
ular, for those drugs for which significant variations in pheno-
typic resistance levels are found in clinical isolates, e.g., isoni-
azid, ethambutol, and streptomycin.
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